Special thanks to my amazing supervisors @ProfSNicholls @ajnelson@clark_ra@PZoungas for their unwavering guidance and support ❤️ A big shoutout to #CybecFoundation for their generous scholarship🙏 Grateful for the opportunity to pursue my research at @MonashVHI@MonashUni ❤️
Meet @MonashVHI PhD candidate and nurse researcher, Trophy Chen.
Her research explores a nurse-led model of care in cardiology prevention to reduce cardiovascular risk for patients with diabetes, with scholarship support from the Cybec Foundation.
More: https://t.co/XP5Nufbb6j
@ruthendacott@2tbueser Deepest thanks to @ruthendacott for connecting us, and to @2tbueser for your mentorship and the wonderful opportunities that followed. Honoured to be part of this collaboration! 💙
Honoured to co-author this @EditorEJCN commentary with the brilliant @2tbueser - thank you for the opportunity to collaborate 💙
A pleasure to explore how #nurse-led holistic approaches can support #cardiac recovery: from #frailty to function 👉 https://t.co/jUmFOsiJQS
1st time at #ISONG2024 and honoured to win 3rd place for my poster! 🎉 Grateful to join the global genetic nurse community and connect with amazing people. Hoping to see an Australian genetic nursing network established soon! @ISONG_news#nurseingenetics#geneticresearch
First time at the Paralympics/Olympics, inspired by every lift, moved by every athlete’s perseverance. Their fearless spirit shows the limitless of what’s possible.Zou Yi, you were incredible 🥇🇨🇳 #Paralympics2024#TeamChina
Have you been an ICU patient or family member who has had a relative in ICU? Join our consumer group to help inform research on family participation in clinical rounds in ICU - complete the form at https://t.co/YOjvQ0FSkp to be part of the group.
@DrPaulineWong@IntensiveCareAu
Did you know you can subscribe to our seminar calendar and view upcoming dates in the series on our website? 💻 Visit: https://t.co/fhSymnfEUA
Our VHI Seminar Series returns next Thursday with Dr Denuja Karunakaran! Read the abstract here: https://t.co/0I52RlKV7g
A trial of the world’s first oral drug for Lp(a) - a previously untreatable form of cholesterol - has been hailed a “gamechanger” in treatment of the condition.
Presented by @ProfSNicholls at @escardio, he says Lp(a) is "cholesterol's evil cousin".
Read: https://t.co/8ixUrARWk1
Tackling the intersection of endocrinology and public health is critical @PZoungas@MonashUni and excellent science communication is pivotal @AAHMS_health
@ProfSNicholls beautifully highlighting the grand challenges and the importance of large randomised controlled trials in cardiology @MonashUni and accelerating medical implementation @AAHMS_health